pp-123 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
China
GMP approvals
China
Comments
Indication: Obesity (adults with BMI ≥30 kg/m² or ≥27 with comorbidity)
Clinical stage: Phase 2 — ongoing in China
Modality: Small molecule (oral GLP-1 receptor agonist)
Mechanism / Target: GLP-1 receptor agonist — promotes insulin secretion, reduces appetite, slows gastric emptying
Route / form: Oral tablet (once daily)
Differentiation: Oral non-peptide GLP-1 agonist; potential dosing convenience advantage vs injectable semaglutide/liraglutide;
Manufacturer #39161
Clinical-stage biotechnology company focused on metabolic and infectious diseases. Develops novel oral small-molecule GLP-1 receptor agonists for obesity. Pursuing wholly owned global development strategy.
None